Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02289898 · ClinicalTrials.gov registry record · Phase 2
Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma
A Phase 2 study, sponsored by OncoMed Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 207
- Enrollment target
NCT02289898 is a Phase 2 study that has completed, run by OncoMed Pharmaceuticals. The registered enrollment target is 207 participants.
The verdict
NCT02289898, a Phase 2 study, has completed, sponsored by OncoMed Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 207 participants
- Enrollment target
Study Summary
This is a randomized, double blind, 3 arm (1:1:1) study in subjects with 1st-line metastatic pancreatic ductal adenocarcinoma. The purpose is to test the efficacy and safety of demcizumab, when given in combination with gemcitabine and Abraxane® compared to placebo. The administration of gemcitabine and Abraxane® is a standard treatment for patients with metastatic pancreatic ductal adenocarcinoma.
Interventions
- DRUG Placebo
- DRUG gemcitabine
- DRUG Demcizumab
- DRUG Abraxane®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 207 participants |
| Start Date | 2015-04-20 |
| Est. Completion | 2017-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02289898
The ClinicalTrials.gov registry entry for NCT02289898 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 207 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OncoMed Pharmaceuticals, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02289898 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02289898 about?
NCT02289898 is a clinical study titled "Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma". This is a randomized, double blind, 3 arm (1:1:1) study in subjects with 1st-line metastatic pancreatic ductal adenocarcinoma. The purpose is to test the efficacy and safety of demcizumab, when given in combination with gemcitabine and Abraxane® compared to placebo. The administration of gemcitabin...
What is the current status of trial NCT02289898?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 207 participants. The study started on 2015-04-20. Estimated completion is 2017-09.
What interventions are being tested in trial NCT02289898?
The interventions under investigation include: Placebo (DRUG), gemcitabine (DRUG), Demcizumab (DRUG), Abraxane® (DRUG).
Who is sponsoring clinical trial NCT02289898?
This trial is sponsored by OncoMed Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.